Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(8):621-628; doi:10.1093/jnci/djh106
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (57)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Cuzick, J.
Right arrow Articles by Duffy, S. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cuzick, J.
Right arrow Articles by Duffy, S. W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

ARTICLE

Tamoxifen and Breast Density in Women at Increased Risk of Breast Cancer

Jack Cuzick, Jane Warwick, Elizabeth Pinney, Ruth M. L. Warren, Stephen W. Duffy

Affiliations of authors: Cancer Research UK, Department of Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary College, University of London, London, U.K. (JC, JW, EP, SWD); Cambridge Breast Unit, Addenbrooke’s Hospital, Cambridge, U.K. (RMLW)

Correspondence to: Jack Cuzick, PhD, Cancer Research UK, Department of Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Charterhouse Square, London, EC1M 6BQ, U.K. (e-mail: jack.cuzick{at}cancer.org.uk)

Background: Although mammographic breast density is associated with the risk of breast cancer and is influenced by hormone levels, the effects of tamoxifen on breast density in healthy women and whether tamoxifen-induced density changes are associated with breast cancer risk are unclear. We investigated mammographic breast density in healthy women with an increased risk of breast cancer at baseline and during 54 months of tamoxifen treatment. Methods: Mammograms were reviewed from 818 breast cancer–free women (388 in the tamoxifen group and 430 in the placebo group) at high risk for breast cancer, from the International Breast Cancer Intervention Study I, a trial of tamoxifen for breast cancer prevention. Breast density measurements, at baseline and during treatment, were obtained at 12- to 18-month intervals. Multivariable analysis was used to assess associations with breast density. All statistical tests were two-sided. Results: Breast density at baseline was similar in placebo (42.6%, 95% confidence interval [CI] = 39.6% to 45.6%) and tamoxifen (41.9%, 95% CI = 38.8% to 45.0%) groups. The main determinants of breast density at baseline were age, menopausal status, body mass index, and previous atypical hyperplasia. A greater density reduction in the tamoxifen group (7.9%, 95% CI = 6.9% to 8.9%) than in the placebo group (3.5%, 95% CI = 2.7% to 4.3%) was apparent within 18 months of treatment (P<.001); the reduction in density continued until 54 months of treatment. After 54 months of tamoxifen treatment, breast density was 28.2% (decrease from baseline = 13.7%, 95% CI = 12.3% to 15.1%; P<.001) in the tamoxifen group and 35.3% (decrease from baseline = 7.3%, 95% CI = 6.1% to 8.4%; P<.001) in the placebo group. The tamoxifen-associated density reduction was apparent in all subgroups, but there was a statistically significant interaction with age. In women aged 45 years or younger at entry, the net reduction with tamoxifen was 13.4% (95% CI = 8.6% to 18.1%), whereas in women older than 55 years, it was 1.1% (95% CI = –3.0% to 5.1%). Conclusion: Tamoxifen treatment was associated with reduction in breast density, most of which occurred during the first 18 months of treatment.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. Eng-Wong, J. Orzano-Birgani, C. K. Chow, D. Venzon, J. Yao, C. E. Galbo, J. A. Zujewski, and S. Prindiville
Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast Cancer
Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1696 - 1701.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
S. Berube, C. Diorio, and J. Brisson
Multivitamin-multimineral supplement use and mammographic breast density
Am. J. Clinical Nutrition, May 1, 2008; 87(5): 1400 - 1404.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. Ding, R. Warren, I. Warsi, N. Day, D. Thompson, M. Brady, C. Tromans, R. Highnam, and D. Easton
Evaluating the Effectiveness of Using Standard Mammogram Form to Predict Breast Cancer Risk: Case-Control Study
Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1074 - 1081.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
L. E. Kelemen, V. S. Pankratz, T. A. Sellers, K. R. Brandt, A. Wang, C. Janney, Z. S. Fredericksen, J. R. Cerhan, and C. M. Vachon
Age-specific Trends in Mammographic Density: The Minnesota Breast Cancer Family Study
Am. J. Epidemiol., May 1, 2008; 167(9): 1027 - 1036.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
T. M. Peters, U. Ekelund, M. Leitzmann, D. Easton, R. Warren, R. Luben, S. Bingham, K.-T. Khaw, and N. J. Wareham
Physical Activity and Mammographic Breast Density in the EPIC-Norfolk Cohort Study
Am. J. Epidemiol., March 1, 2008; 167(5): 579 - 585.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Decensi, S. Gandini, D. Serrano, M. Cazzaniga, M. Pizzamiglio, F. Maffini, G. Pelosi, C. Daldoss, U. Omodei, H. Johansson, et al.
Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users
J. Clin. Oncol., September 20, 2007; 25(27): 4201 - 4209.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. J. Fabian
Low-Dose Tamoxifen for Combination Hormone Replacement Therapy Users
J. Clin. Oncol., September 20, 2007; 25(27): 4162 - 4164.
[Full Text] [PDF]


Home page
Cancer Res.Home page
C. M. Vachon, T. A. Sellers, E. E. Carlson, J. M. Cunningham, C. A. Hilker, R. L. Smalley, D. J. Schaid, L. E. Kelemen, F. J. Couch, and V. S. Pankratz
Strong Evidence of a Genetic Determinant for Mammographic Density, a Major Risk Factor for Breast Cancer
Cancer Res., September 1, 2007; 67(17): 8412 - 8418.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
R. M. Tamimi, C. Byrne, G. A. Colditz, and S. E. Hankinson
Endogenous Hormone Levels, Mammographic Density, and Subsequent Risk of Breast Cancer in Postmenopausal Women
J Natl Cancer Inst, August 1, 2007; 99(15): 1178 - 1187.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. M. Vachon, V. S. Pankratz, C. G. Scott, S. D. Maloney, K. Ghosh, K. R. Brandt, T. Milanese, M. J. Carston, and T. A. Sellers
Longitudinal Trends in Mammographic Percent Density and Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 921 - 928.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. L. Irwin, E. J. Aiello, A. McTiernan, L. Bernstein, F. D. Gilliland, R. N. Baumgartner, K. B. Baumgartner, and R. Ballard-Barbash
Physical Activity, Body Mass Index, and Mammographic Density in Postmenopausal Breast Cancer Survivors
J. Clin. Oncol., March 20, 2007; 25(9): 1061 - 1066.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
K. Kerlikowske, L. Ichikawa, D. L. Miglioretti, D. S. M. Buist, P. M. Vacek, R. Smith-Bindman, B. Yankaskas, P. A. Carney, and R. Ballard-Barbash
Longitudinal Measurement of Clinical Mammographic Breast Density to Improve Estimation of Breast Cancer Risk
J Natl Cancer Inst, March 7, 2007; 99(5): 386 - 395.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. N. Weitzel, S. S. Buys, W. H. Sherman, A. M. Daniels, G. Ursin, J. R. Daniels, D. J. MacDonald, K. R. Blazer, M. C. Pike, and D. V. Spicer
Reduced Mammographic Density with Use of a Gonadotropin-Releasing Hormone Agonist-Based Chemoprevention Regimen in BRCA1 Carriers
Clin. Cancer Res., January 15, 2007; 13(2): 654 - 658.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. M. Vachon, K. R. Brandt, K. Ghosh, C. G. Scott, S. D. Maloney, M. J. Carston, V. S. Pankratz, and T. A. Sellers
Mammographic Breast Density as a General Marker of Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 43 - 49.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
N. F. Boyd, L. J. Martin, L. Sun, H. Guo, A. Chiarelli, G. Hislop, M. Yaffe, and S. Minkin
Body Size, Mammographic Density, and Breast Cancer Risk.
Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2086 - 2092.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
C. J. Fabian and B. F. Kimler
Mammographic Density: Use in Risk Assessment and as a Biomarker in Prevention Trials
J. Nutr., October 1, 2006; 136(10): 2705S - 2708S.
[Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
R. Warren, J. Skinner, E. Sala, E. Denton, M. Dowsett, E. Folkerd, C. S. Healey, A. Dunning, D. Doody, B. Ponder, et al.
Associations among Mammographic Density, Circulating Sex Hormones, and Polymorphisms in Sex Hormone Metabolism Genes in Postmenopausal Women.
Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1502 - 1508.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. R. Palomares, J. R.B. Machia, C. D. Lehman, J. R. Daling, and A. McTiernan
Mammographic density correlation with gail model breast cancer risk estimates and component risk factors.
Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1324 - 1330.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
V. A. McCormack and I. dos Santos Silva
Breast Density and Parenchymal Patterns as Markers of Breast Cancer Risk: A Meta-analysis.
Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1159 - 1169.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
N. F. Boyd, L. J. Martin, Q. Li, L. Sun, A. M. Chiarelli, G. Hislop, M. J. Yaffe, and S. Minkin
Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer.
Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 961 - 966.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Guerrieri-Gonzaga, C. Robertson, B. Bonanni, D. Serrano, M. Cazzaniga, S. Mora, M. Gulisano, H. Johansson, F. Formelli, M. Intra, et al.
Preliminary Results on Safety and Activity of a Randomized, Double-Blind, 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in Premenopausal Women
J. Clin. Oncol., January 1, 2006; 24(1): 129 - 135.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
R. M. Tamimi, S. E. Hankinson, G. A. Colditz, and C. Byrne
Endogenous Sex Hormone Levels and Mammographic Density among Postmenopausal Women
Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2641 - 2647.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Radiol.Home page
M K Simick and L Lilge
Optical transillumination spectroscopy to quantify parenchymal tissue density: an indicator for breast cancer risk
Br. J. Radiol., November 1, 2005; 78(935): 1009 - 1017.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. McTiernan, C. F. Martin, J. D. Peck, A. K. Aragaki, R. T. Chlebowski, E. D. Pisano, C. Y. Wang, R. L. Brunner, K. C. Johnson, J. E. Manson, et al.
Estrogen-Plus-Progestin Use and Mammographic Density in Postmenopausal Women: Women's Health Initiative Randomized Trial
J Natl Cancer Inst, September 21, 2005; 97(18): 1366 - 1376.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
G. S. Dite, J. D. Wark, G. G. Giles, D. R. English, M. R.E. McCredie, and J. L. Hopper
Is There Overlap Between the Genetic Determinants of Mammographic Density and Bone Mineral Density?
Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2266 - 2268.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. Berube, C. Diorio, B. Masse, N. Hebert-Croteau, C. Byrne, G. Cote, M. Pollak, M. Yaffe, and J. Brisson
Vitamin D and Calcium Intakes from Food or Supplements and Mammographic Breast Density
Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1653 - 1659.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
C J Fabian, B F Kimler, M S Mayo, and S A Khan
Breast-tissue sampling for risk assessment and prevention
Endocr. Relat. Cancer, June 1, 2005; 12(2): 185 - 213.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. J. Fabian and B. F. Kimler
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655.
[Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
K. Kerlikowske, J. Shepherd, J. Creasman, J. A. Tice, E. Ziv, and S. R. Cummings
Are Breast Density and Bone Mineral Density Independent Risk Factors for Breast Cancer?
J Natl Cancer Inst, March 2, 2005; 97(5): 368 - 374.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
E. Ziv, J. Tice, R. Smith-Bindman, J. Shepherd, S. Cummings, and K. Kerlikowske
Mammographic Density and Estrogen Receptor Status of Breast Cancer
Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2090 - 2095.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.